• Therapeutic supprot of hepatobiliar system in obsetrician / gynecologist practice

Therapeutic supprot of hepatobiliar system in obsetrician / gynecologist practice

HEALTH OF WOMAN. 2017.10(126):79–82; doi 10.15574/HW.2017.126.79

Gopchuk O.
National Medical Academy of Postgraduate Education P. L. Shupyk, Kiev

The latest data about mechanisms of liver damage due to use of medication treatment is presented in the article. It presents the information about new hepatoprotecive drugs for preventing hepatotoxicity in curative schemes of gynecologic pathologies.
Key words: hepatoprotectors, liver, LESIL, essential phospholipids, silimarin, phytosome, treatment, prevention.

REFERENCES

1. Zvyagintseva TD. Chernobay AI. 2014. Khronicheskiye zabolevaniya pecheni: fokus na polikompozitsionnyye rastitelnyye gepatoprotektory antioksidanty. Suchasna gastroyenterologіya 4:70–76.

2. Verma S, Thuluvath PJ. 2017. Complementary and alternative medicine in hepatology: review of the evidence of efficacy. Clin Gastroenterol Hepatol. 5(4):408–416.

3. Flora K, Hahn M, Rosen H. 2016. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol. 93(2):139–143.

4. Oskanova RS. Ilchenko LYu. Fedorov IG. 2013. Khronicheskiye zabolevaniya pecheni – ot patogeneza k lecheniyu. Farmateka 14:62–66.

5. Zhilkina VYu. Marakhova AI. Kezimana P. 2015. Fitosomy – innovatsionnaya tekhnologiya dostavki rastitelnykh komponentov. Uspekhi sovremennogo estestvoznaniya 11–1:31–34.

6. Barzaghi N, Crema F, Gatti G. 1990. Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects. Eur J Drug Metab Pharmacokinet. 15:333–338.

7. Chernyavskiy VV. 2013. Vospalitelnyy protsess pri khronicheskikh zabolevaniyakh pecheni: vozmozhnyye terapevticheskiye podkhody. Praktikuyuchiy lіkar 3:38–42.

8. Vasilevskaya AS. 2013. Gepatoprotektory v ustranenii povrezhdeniy pecheni. Eksperimentalnaya i klinicheskaya gastroenterologiya 12:22–28.

9. Buyeverov AO. Bogomolov PO. Buyeverova EL. 2015. Gepatotoksichnost antibakterialnykh preparatov v terapevticheskoy praktike. Klin. mikrobiol. antimikrob. khimioter. 17;3:207–216.

10. Borys OM, Tupis OIa, Hak IO ta in. 2009. Rol hepatoprotektoriv u skladi kompleksnoho likuvannia fetoplatsentarnoi nedostatnosti u vahitnykh iz preeklampsiieiu ta urazhenniam hepatobiliarnoi systemy. Zdorove zhenshchynу 6(42):79–84.

11. Nikitin IG. 2007. Gepatoprotektory: mify i realnyye vozmozhnosti. Farmateka.

12. Ferenci P, Dragosics B, Dittrich H. 2016. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol. 9(1):105–113. https://doi.org/10.1016/0168-8278(89)90083-4

13. Kondrackiene J, Kupcinskas L. 2017. Intrahepatic cholestasis of pregnancy-current achievements and unsolved problems. World J Gastroenterol. 14(38):5781–5788. https://doi.org/10.3748/wjg.14.5781; PMCid:PMC2751886

14. Kayynbayeva AK. 2016. Gepatoprotektornyy effekt preparata rastitelnogo proiskhozhdeniya. Vestnik KazNU; Seriya Ekologicheskaya. 35;3:42–48.

15. Skrypnik IN. 2013. Otsenka terapevticheskikh podkhodov k lecheniyu nealkogolnogo steatogepatita v Ukraine i ego vzaimosvyaz s faktorami riska: rezultaty otkrytogo multitsentrovogo prospektivnogo issledovaniya DIREG_L_04443. Suchasna gastroyenterologіya 2:64–71.